Loading
A phase 1/2 trial of upifitamab rilsodotin in ovarian cancer and non-small-cell lung cancer, run by Mersana Therapeutics, active and no longer recruiting.
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b is a phase 1/2 interventional study registered as NCT03319628 by Mersana Therapeutics, with 523 participants enrolled, started 2017-12-12 and due to reach its primary completion in 2023-05-31. Interventions recorded: upifitamab rilsodotin.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.